"A-431人表皮癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

常見(jiàn)細(xì)胞貼壁較弱原因：在遇到運(yùn)輸?shù)蜏丶罢鹗帯⑹覝仂o置太長(zhǎng)時(shí)間、添加的培養(yǎng)基或其他試劑過(guò)冷、密度較高、聚集未吹散、加液吹打到細(xì)胞面等情況時(shí)會(huì)出現(xiàn)明顯的成片脫落現(xiàn)象，此時(shí)若脫落現(xiàn)象不嚴(yán)重應(yīng)盡快放回培養(yǎng)基繼續(xù)培養(yǎng)，若呈大片脫落的情況時(shí)需要收集細(xì)胞重新消化吹散并接種；建議使用經(jīng)過(guò)包被或者高貼壁培養(yǎng)瓶培養(yǎng)細(xì)胞，盡量避免接觸低溫或密度過(guò)高。

換液周期：每周2-3次

K1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：McCoy B細(xì)胞、PLA-802細(xì)胞、PNEC30細(xì)胞

SU-DHL-16 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RH8994細(xì)胞、NPC-TW 01細(xì)胞、H184A1細(xì)胞

HEC-1A Cells;背景說(shuō)明：這株細(xì)胞及其亞株HEC-１-B是H.Kuramoto及其同事１９６８年從一位IA期子宮內(nèi)膜癌患者身上分離得到的。PAF可以誘導(dǎo)其c-fos的表達(dá)。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Oka-C1細(xì)胞、SK Col 1細(xì)胞、OEC33細(xì)胞

A-431人表皮癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：該細(xì)胞源自一位患有皮膚鱗狀細(xì)胞癌的８５歲女性，是GiardDJ等人建立的一系列細(xì)胞株中的一株。該細(xì)胞在免疫抑制小鼠體內(nèi)可成瘤，在瓊脂上培養(yǎng)可形成克??；是一個(gè)超三倍體人細(xì)胞株。

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測(cè)；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺(tái)，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長(zhǎng)特性和后續(xù)的實(shí)驗(yàn)需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長(zhǎng)的比較快，不是著急用的話，我就會(huì)按1E6個(gè)細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會(huì)適當(dāng)多傳一點(diǎn)；還可通過(guò)顯微鏡計(jì)數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實(shí)驗(yàn)。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

A-431人表皮癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來(lái)源：人源、鼠源等其它物種來(lái)源

SF 295 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA-MB 453細(xì)胞、SW-1116細(xì)胞、HuP-T3細(xì)胞

WM 2664 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：TE-9細(xì)胞、SK-MEL24細(xì)胞、MV411細(xì)胞

293 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NPA87細(xì)胞、HT-144細(xì)胞、A875細(xì)胞

HOPC Cells;背景說(shuō)明：少突膠質(zhì)前體 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：UACC-893細(xì)胞、Normal Rat Kidney細(xì)胞、H209細(xì)胞

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞培養(yǎng)無(wú)菌操作步驟和注意事項(xiàng)：１.打開(kāi)無(wú)菌工作臺(tái)及凈化室的紫外燈，消毒半小時(shí)以上。２.進(jìn)入凈化室前先關(guān)閉紫外燈，打開(kāi)超凈臺(tái)風(fēng)機(jī)，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風(fēng)淋２分鐘。５.０.１%水泡手，擦干。６.點(diǎn)燃酒精燈;超凈臺(tái)內(nèi)應(yīng)避免放入過(guò)多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開(kāi)各類(lèi)瓶蓋前先過(guò)火，以固定灰塵;打開(kāi)的瓶口、試管口過(guò)火焰，鑷子使用前應(yīng)經(jīng)火焰燒灼。８.水平式風(fēng)機(jī)的超凈臺(tái)，應(yīng)使瓶口斜置，應(yīng)盡量避免瓶口敞開(kāi)直立。９.同一根吸管或滴管不應(yīng)連續(xù)用于幾個(gè)不同的細(xì)胞系；吸取培養(yǎng)基的吸管應(yīng)離開(kāi)培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細(xì)胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺(tái)上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復(fù)工作臺(tái)面。

CV 1 Cells;背景說(shuō)明：CV-１細(xì)胞株是１９６４年由JensenFC等建系的，源自成年雄性非洲綠猴腎，被用于Rous肉瘤病毒的轉(zhuǎn)染研究。可作為SV４０載體的轉(zhuǎn)染宿主。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：hADSCs細(xì)胞、BALL-1細(xì)胞、Z310細(xì)胞

G402 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：６傳代，每周２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MOLP2細(xì)胞、TE353.SK細(xì)胞、PANC403細(xì)胞

SKOV-433 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H1703細(xì)胞、Hs 729.T細(xì)胞、MC-26細(xì)胞

RLE-6TN Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：C3H10T1/2CL8細(xì)胞、U-251MG細(xì)胞、RWPE-1細(xì)胞

Tb 1 Lu Cells;背景說(shuō)明：肺;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MCF.10A細(xì)胞、BEL 7402細(xì)胞、NHRF細(xì)胞

JROECL 33 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HOCF細(xì)胞、BHK細(xì)胞、C3H10T1/2CL8細(xì)胞

Colo205 Cells;背景說(shuō)明：該細(xì)胞系是１９５７年由T.U.Sample等從患有結(jié)腸癌的７０歲男性白人的腹水中分離的。該病人在取腹水樣品前已用５-尿嘧啶治療４~６周。角蛋白免疫過(guò)氧化物酶染色陽(yáng)性；產(chǎn)生CEA、IL１０。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KBM-7細(xì)胞、RAG細(xì)胞、MHCC 97細(xì)胞

HS0578T Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：L cells (TK-)細(xì)胞、TK 10細(xì)胞、MGc80-3細(xì)胞

COLO679 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：EPC細(xì)胞、Hs-940細(xì)胞、SCH細(xì)胞

HTR8svn Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HCC-9204細(xì)胞、Panc3_27細(xì)胞、HT-144細(xì)胞

H295R-S1 Cells;背景說(shuō)明：腎上腺皮質(zhì)癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：AU565細(xì)胞、AN3-CA細(xì)胞、HEK-2細(xì)胞

DSL-6A/C1 Cells;背景說(shuō)明：胰腺癌；雄性；Lewis;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：OVCAR-420細(xì)胞、MDA175細(xì)胞、A427細(xì)胞

SGC-7901/DDP Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CCD-841CoTr細(xì)胞、DHL5細(xì)胞、LLCPK1細(xì)胞

Ramos (RA 1) Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：hESC細(xì)胞、K7M2 wt細(xì)胞、SW-1990細(xì)胞

HCC-70 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Swiss/3T3細(xì)胞、HBL100細(xì)胞、C8D1A細(xì)胞

THP1 Cells;背景說(shuō)明：該細(xì)胞從一名１歲的患有急性單核細(xì)胞性白血病的男孩的外周血中分離建立。該細(xì)胞可以吞噬乳膠顆粒和激活的紅細(xì)胞，細(xì)胞膜和胞漿內(nèi)均沒(méi)有免疫球蛋白，表達(dá)C３R和FcR；可受佛波酯TPA誘導(dǎo)向單核系方向分化；可作為轉(zhuǎn)染宿主。;傳代方法：維持細(xì)胞濃度在２-４×１０５-８×１０５/ml，勿超過(guò)１×１０６/ml；２-３天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：?jiǎn)魏思?xì)胞;相關(guān)產(chǎn)品有：HBVP細(xì)胞、WM115-mel細(xì)胞、MUTZ3細(xì)胞

HCT_116 Cells;背景說(shuō)明：結(jié)腸腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RT4-D6P2T細(xì)胞、Hs-675-T細(xì)胞、WB F344細(xì)胞

Abcam A-549 LYN KO Cells(提供STR鑒定圖譜)

Abcam U-87MG TH KO Cells(提供STR鑒定圖譜)

BayGenomics ES cell line CSG191 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRT699 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTC561 Cells(提供STR鑒定圖譜)

CHO Pro-4 MtxRII-2-1 Cells(提供STR鑒定圖譜)

DA02402 Cells(提供STR鑒定圖譜)

DA05907 Cells(提供STR鑒定圖譜)

GM00248 Cells(提供STR鑒定圖譜)

IOSE-80 Cells;背景說(shuō)明：卵巢；上皮細(xì)胞；SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：mouse Inner Medullary Collecting Duct-3細(xì)胞、LO2細(xì)胞、H1781細(xì)胞

A-431人表皮癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

MDCK Type II Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代，３-４天傳１次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：LMH細(xì)胞、Michigan Cancer Foundation-12F細(xì)胞、HEC-1A細(xì)胞

HNEpC Cells;背景說(shuō)明：鼻粘膜；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Jurkat-77細(xì)胞、M-NFS-60細(xì)胞、C4-I細(xì)胞

PL12 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：16HBE140細(xì)胞、PA-TU-8988S細(xì)胞、HIBEpiC細(xì)胞

Ly3 Cells;背景說(shuō)明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H295R細(xì)胞、MDA-MB-330細(xì)胞、LLC-WRC 256細(xì)胞

CAKI.1 Cells;背景說(shuō)明：該細(xì)胞超微結(jié)構(gòu)中包含許多微絨毛、少許微絲、許多小線粒體、發(fā)達(dá)的高爾基休和內(nèi)質(zhì)網(wǎng)、許多脂滴和多層體、次級(jí)溶酶體，沒(méi)有發(fā)現(xiàn)病毒顆粒。;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SK-ChA1細(xì)胞、NKM1細(xì)胞、HGMC細(xì)胞

28-12 Cells(提供STR鑒定圖譜)

OEC19 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：TE671細(xì)胞、PE/CA-PJ34細(xì)胞、Mia PACA 2細(xì)胞

JURKAT E-61 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MT-4細(xì)胞、WM-2664細(xì)胞、HNEpC細(xì)胞

SBC3 Cells;背景說(shuō)明：小細(xì)胞肺癌；骨髓轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：L-M[TK-]細(xì)胞、RPE1細(xì)胞、WERI Rb-1細(xì)胞

SNU119 Cells;背景說(shuō)明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA1386細(xì)胞、MUTZ-3細(xì)胞、CL1-0細(xì)胞

686LN-M4e Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HSC-2細(xì)胞、Dx5細(xì)胞、786-O RCC細(xì)胞

SNU-668 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Mac-1細(xì)胞、EU-4細(xì)胞、NCI-H660細(xì)胞

SNU-668 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Mac-1細(xì)胞、EU-4細(xì)胞、NCI-H660細(xì)胞

Leukemic 1210 Cells;背景說(shuō)明：該細(xì)胞源于用０.２%甲基膽蒽（溶解）涂抹雌性小鼠的皮膚誘發(fā)的腫瘤，鼠痘病毒陰性。;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-H2108細(xì)胞、H-1693細(xì)胞、Co320細(xì)胞

HAP1 ACHE (-) 1 Cells(提供STR鑒定圖譜)

HAP1 SEC31B (-) 2 Cells(提供STR鑒定圖譜)

T-HEECs Cells;背景說(shuō)明：食管；上皮細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：QBI-HEK 293A細(xì)胞、MV4;11細(xì)胞、MDA134細(xì)胞

SKCO1 Cells;背景說(shuō)明：該細(xì)胞來(lái)源于結(jié)直腸病人的轉(zhuǎn)移性腹水。;傳代方法：１：２-１：３傳代，每周２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：PC3M-1E8細(xì)胞、NG108-15細(xì)胞、RBVEC細(xì)胞

WM115mel Cells;背景說(shuō)明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Panc203細(xì)胞、HTori-3.1細(xì)胞、UCLA RO-81A-1細(xì)胞

HCC78 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SK-N-SH細(xì)胞、SK-MEL2細(xì)胞、SW-837細(xì)胞

HCC2218 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２—３次;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Hs 819.T細(xì)胞、rHSC-99細(xì)胞、HCC-78細(xì)胞

H-1993 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：６傳代;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Panc02細(xì)胞、Wistar Institute, Susan Hayflick細(xì)胞、293A細(xì)胞

Mo7e Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H-2196細(xì)胞、CAKI 2細(xì)胞、NCI-H510細(xì)胞

ROS17/28 Cells;背景說(shuō)明：骨肉瘤；ACI ９９３５;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Immortalized Human Hepatocytes細(xì)胞、MC57G細(xì)胞、IGROV-1細(xì)胞

HyCyte HEK293T KO-hTIMD4 Cells(提供STR鑒定圖譜)

LCA1-hiPSC2 Cells(提供STR鑒定圖譜)

Mz35 Cells(提供STR鑒定圖譜)

OV2944-LM-3 Cells(提供STR鑒定圖譜)

RR-H460 Cells(提供STR鑒定圖譜)

Ubigene HTR-8/SVneo GSDMB KO Cells(提供STR鑒定圖譜)

Y1-Forsk-10r-1 Cells(提供STR鑒定圖譜)

HG01114 Cells(提供STR鑒定圖譜)

293/EBNA-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SK_N_FI細(xì)胞、Ly3細(xì)胞、U2-OS細(xì)胞

BLO 11 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：COR-L105細(xì)胞、HEK-2細(xì)胞、MKN28細(xì)胞

Panc 4.03 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：WEHI-3細(xì)胞、RTE細(xì)胞、NCI-H2452細(xì)胞

COLO-738 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Roswell Park Memorial Institute 1846細(xì)胞、M3 Clone M-3細(xì)胞、GM05862細(xì)胞

RPE-1 Cells;背景說(shuō)明：視網(wǎng)膜色素上皮；hTERT永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Human Hepatocyte Line 5細(xì)胞、H-1793細(xì)胞、HFLS細(xì)胞

RPE-1 Cells;背景說(shuō)明：視網(wǎng)膜色素上皮；hTERT永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Human Hepatocyte Line 5細(xì)胞、H-1793細(xì)胞、HFLS細(xì)胞

FU-97 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCl-H157細(xì)胞、MAD109細(xì)胞、Hs819T細(xì)胞

Jurkat-FHCRC Cells;背景說(shuō)明：該細(xì)胞源自一位１４歲患有T淋巴細(xì)胞白血病男性的外周血;傳代方法：保持細(xì)胞密度在３—９×１０５cells/ml之間，１：５—１：１０傳代，每周換液２—３次;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：圓形，單個(gè)或呈片;相關(guān)產(chǎn)品有：SNK-1細(xì)胞、SKLMS1細(xì)胞、H-508細(xì)胞

HTR8svn Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HCC-9204細(xì)胞、Panc3_27細(xì)胞、HT-144細(xì)胞

GM00637B Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Neukoplast細(xì)胞、L-M(TK-)細(xì)胞、alphaTC1 Clone 6細(xì)胞

Roswell Park Memorial Institute 1788 Cells;背景說(shuō)明：B淋巴細(xì)胞；EBV轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：EM3細(xì)胞、SGC7901/DDP細(xì)胞、C3H10T1/2細(xì)胞

Roswell Park Memorial Institute 2650 Cells;背景說(shuō)明：頭頸鱗癌；胸腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LPC-H12細(xì)胞、NCI-H1417細(xì)胞、Duke University 145細(xì)胞

B-cell Acute Lymphoblastic Leukemia-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：SMMC7721細(xì)胞、NCI-HUT-460細(xì)胞、LSC-1細(xì)胞

PCI-4M Cells;背景說(shuō)明：喉鱗癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：hTERT RPE1細(xì)胞、52PE細(xì)胞、WM451Lu細(xì)胞

CDC/EU.HMEC-1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NCIH2227細(xì)胞、SKN-SH細(xì)胞、NCI-H209細(xì)胞

TD3 Cells(提供STR鑒定圖譜)

FL62891 Cells;背景說(shuō)明：肝；SV４０轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PCI-SG231細(xì)胞、SNU-601細(xì)胞、SNU-668細(xì)胞

Capan-2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多邊形;相關(guān)產(chǎn)品有：H-1341細(xì)胞、NOR 10細(xì)胞、NG10815細(xì)胞

Bronchial Epithelium transformed with Ad12-SV40 2B Cells;背景說(shuō)明：從一位非癌個(gè)體的正常人支氣管上皮病理切片分離出上皮細(xì)胞。這些細(xì)胞用腺病毒１２-SV４０病毒雜交病毒感染并克隆。DEAS-２B細(xì)胞保留了對(duì)血清反應(yīng)進(jìn)行鱗關(guān)分化的能力，并有用于篩選誘導(dǎo)或影響分化及致癌的化學(xué)或生物制劑。細(xì)胞角蛋白及SV４０抗原染色陽(yáng)性。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：QBC(939)細(xì)胞、JB 6細(xì)胞、HIT T15細(xì)胞

H-2342 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：６傳代 ;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCT116/L細(xì)胞、LoVo細(xì)胞、H1563細(xì)胞

TE9 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：GM03569細(xì)胞、NCIH838細(xì)胞、RPMI-6666細(xì)胞

HCV29 Cells;背景說(shuō)明：膀胱；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：GS9L細(xì)胞、HCC-1171細(xì)胞、WEHI 164細(xì)胞

A-431人表皮癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

HOS(TE85) Cells;背景說(shuō)明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HAVSMC細(xì)胞、NCI-841細(xì)胞、NCIH2347細(xì)胞

H69 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長(zhǎng)特性：懸浮生長(zhǎng)，聚團(tuán);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：KYSE-50細(xì)胞、Ontario Cancer Institute-Acute Myeloid Leukemia-4細(xì)胞、PG [Human lung carcinoma]細(xì)胞

SF17 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HCC2157細(xì)胞、OCI-Ly3細(xì)胞、SK-N-BE-2細(xì)胞

EoL-1-cell Cells;背景說(shuō)明：急性髓系白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BRL細(xì)胞、Beta-TC-6細(xì)胞、MNNGHOS細(xì)胞

NOR10 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-SNU-387細(xì)胞、HB611細(xì)胞、SPDC-CCL141細(xì)胞

MDCC-MSB-1 Cells;背景說(shuō)明：淋巴瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：C-33-A細(xì)胞、SUP-M2細(xì)胞、Co320細(xì)胞

HSC-3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１ x １０^５ cells/１０cm dish;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HT-29/CX-1細(xì)胞、SUD-4細(xì)胞、NCIH2452細(xì)胞

CCD 841 CoN Cells;背景說(shuō)明：結(jié)腸上皮細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：RERF-LC-MS細(xì)胞、HTR8svn細(xì)胞、Hep II細(xì)胞

BayGenomics ES cell line CSH029 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRU414 Cells(提供STR鑒定圖譜)

BBG-30 Cells(提供STR鑒定圖譜)

Keck MirKO ES cell line Mirc24 Cells(提供STR鑒定圖譜)

PCRP-ZNF296-1D6 Cells(提供STR鑒定圖譜)

ND23 Cells(提供STR鑒定圖譜)

" "PubMed=22282976; DOI=10.1093/carcin/1.1.21

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.

Human tumor cell strains defective in the repair of alkylation damage.

Carcinogenesis 1:21-32(1980)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157

Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.

Differential expression of the amv gene in human hematopoietic cells.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6983291; DOI=10.1002/aja.1001650207

Barka T., van der Noen H.M.

Culture of A-431 human epidermoid carcinoma cells in serum-free medium: effect of culture conditions on the binding of [125I]-epidermal growth factor.

Am. J. Anat. 165:187-198(1982)

PubMed=6092175; DOI=10.1016/0303-7207(84)90053-4

Gamou S., Kim Y.S., Shimizu N.

Different responses to EGF in two human carcinoma cell lines, A431 and UCVA-1, possessing high numbers of EGF receptors.

Mol. Cell. Endocrinol. 37:205-213(1984)

PubMed=6500159; DOI=10.1159/000163283

Gershwin M.E., Lentz D., Owens R.B.

Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.

Exp. Cell Biol. 52:361-370(1984)

PubMed=2990217; PMCID=PMC1888002

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Am. J. Pathol. 119:361-366(1985)

PubMed=2758419

Pekkola-Heino K., Kulmala J., Grenman S.E., Carey T.E., Grenman R.

Radiation response of vulvar squamous cell carcinoma (UM-SCV-1A, UM-SCV-1B, UM-SCV-2, and A-431) cells in vitro.

Cancer Res. 49:4876-4878(1989)

PubMed=2228902; DOI=10.1007/BF02624609

Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.

Growth of the malignant and nonmalignant human squamous cells in a protein-free defined medium.

In Vitro Cell. Dev. Biol. 26:849-856(1990)

PubMed=1394225

Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., Casey G.

Frequent p53 mutations in head and neck cancer.

Cancer Res. 52:5997-6000(1992)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9887230; DOI=10.1006/gyno.1998.5194

Rantanen V., Grenman S.E., Kurvinen K., Hietanen S.H., Raitanen M., Syrjanen S.M.

p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.

Gynecol. Oncol. 71:352-358(1998)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=17178626; DOI=10.1080/09553000600969812

Kurvinen K., Rantanen V., Syrjanen S.M., Johansson B.

Radiation-induced effects on telomerase in gynecological cancer cell lines with different radiosensitivity and repair capacity.

Int. J. Radiat. Biol. 82:859-867(2006)

PubMed=18568074; DOI=10.1172/JCI34588; PMCID=PMC2430495

Guix M., Faber A.C., Wang S.-Z.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A.

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

J. Clin. Invest. 118:2609-2619(2008)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=22108792; DOI=10.1038/msb.2011.84; PMCID=PMC3261715

Munoz J., Low T.Y., Kok Y.J., Chin A., Frese C.K., Ding V., Choo A.B.-H., Heck A.J.R.

The quantitative proteomes of human-induced pluripotent stem cells and embryonic stem cells.

Mol. Syst. Biol. 7:550-550(2011)

PubMed=23637631; DOI=10.1371/journal.pgen.1003464; PMCID=PMC3636093

Giacomini C.P., Sun S., Varma S., Shain A.H., Giacomini M.M., Balagtas J.M.S., Sweeney R.T., Lai E., Del Vecchio C.A., Forster A.D., Clarke N., Montgomery K.D., Zhu S., Wong A.J., van de Rijn M., West R.B., Pollack J.R.

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.

PLoS Genet. 9:E1003464-E1003464(2013)

PubMed=24804581; DOI=10.1021/cb500116c

Giansanti P., Preisinger C., Huber K.V.M., Gridling M., Superti-Furga G., Bennett K.L., Heck A.J.R.

Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.

ACS Chem. Biol. 9:1490-1498(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26989177; DOI=10.1242/dev.133728; PMCID=PMC4874484

Elbediwy A., Vincent-Mistiaen Z.I., Spencer-Dene B., Stone R.K., Boeing S., Wculek S.K., Cordero J., Tan E.H., Ridgway R., Brunton V.G., Sahai E., Gerhardt H., Behrens A., Malanchi I., Sansom O.J., Thompson B.J.

Integrin signalling regulates YAP and TAZ to control skin homeostasis.

Development 143:1674-1687(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)"